Ranbaxy Laboratories Ltd has introduced two new anti-HIV products, Virolis-E and Virocomb-E in India. Both products contain three Anti Retroviral drugs each and offer WHO recommended first line Highly Active Anti Retroviral Therapy (HAART) in convenient daily use packs.

According to the company release, the products are designed to improve compliance with HAART which is presently a challenge faced by both patients and healthcare providers. In most countries outside India, these products will be labelled and sold under the Coviro-E and Avocomb-E brand names respectively.

Virolis-E is a compliance pack containing two fixed dose combination tablets of Lamivudine 150 mg & Stavudine 30 / 40 mg and one tablet of Efavirenz 600 mg.

Virocomb-E is also a compliance pack & contains two fixed dose combination tablets of Lamivudine 150 mg & Zidovudine 300 mg and one tablet of Efavirenz 600 mg.

Dr Brian Tempest CEO and MD of the Company said - "We are pleased to introduce the innovative products, Virolis-E and Virocomb-E that aim to make HIV treatment easier to administer and use. Ranbaxy is committed to HIV care and this is yet another step in our endeavour to make high quality, affordable and patient friendly ARVs available worldwide."

Virolis-E and Virocomb-E are indicated for treatment of HIV-I infection. These products will make available Efavirenz based HAART regimens in convenient daily packs in addition to the convenient Nevirapine based regimens already made available by the Company, added the release.